Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director · Chief Business Officer | December 02, 2021 | December 02, 2021 |
| ONCOLYTICS BIOTECH INCONCY · Entity 6721 | Director | June 01, 2026 | June 03, 2026 |
| SteadyMed Ltd.STDY · Entity 163743 | Director · President and CEO | August 30, 2018 | September 04, 2018 |
| XERIS PHARMACEUTICALS INCXERS · Entity 134906 | Director | February 27, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 02, 2021
This filing explicitly reported no securities owned.
ONCOLYTICS BIOTECH INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2036-06-01 | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
SteadyMed Ltd.
Report date August 30, 2018 · Filed September 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-30 · Sale · Disposed 41,605 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2018-08-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-08-30 · Sale · Disposed 4,960 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2020-05-01 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-30 · Other · Disposed 18,515 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2021-07-07 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-08-30 · Other · Disposed 145,212 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2022-01-25 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-08-30 · Other · Disposed 131,451 · Balance 0 F3: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2026-06-17 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-08-30 · Other · Disposed 63,764 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2027-12-28 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-08-30 · Other · Disposed 163,394 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone").
F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
F3: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time
XERIS PHARMACEUTICALS INC
Report date February 27, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2029-02-27 | Direct | 20,000 |
Reported balance
After 2019-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-27 · Grant · Acquired 20,000 · Balance 20,000 F1: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-26-027097 · ownership.xml · derivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:35 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005457 · doc4.xml · derivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 163,394 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · derivative · entry 7 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 163,394 shares Expires 2027-12-28 F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 63,764 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · derivative · entry 6 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 63,764 shares Expires 2026-06-17 F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 131,451 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · derivative · entry 5 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 131,451 shares Expires 2022-01-25 F3 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time F3 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 145,212 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · derivative · entry 4 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 145,212 shares Expires 2021-07-07 F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | OtherStock Option (Rt to Buy) · Derivative | 18,515 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · derivative · entry 3 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,515 shares Expires 2020-05-01 F2 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. F2 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 4,960 | $4.46 | $22,121.60 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · nonDerivative · entry 2 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 19:40 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 41,605 | $4.46 | $185,558.30 |
DisclosureSEC source: 0001209191-18-049375 · doc4.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F1 · balance_after: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,994 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · derivative · entry 6 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,097 Underlying: Ordinary Shares · 16,994 shares Expires 2026-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 33% of the Option Shares shall vest on the one-year anniversary of the grant date. Thereafter, the remainder of the Option Shares shall vest in 8 equal amounts every 3 months beginning 3 months after the one-year anniversary date. Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 16,994 | $4.70 | $79,871.80 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · nonDerivative · entry 4 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,605 Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionOrdinary Shares | 16,994 | $2.74 | $46,563.56 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · nonDerivative · entry 3 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionStock Options (Right to Buy) · Derivative | 44,242 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · derivative · entry 5 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,091 Underlying: Ordinary Shares · 44,242 shares Expires 2026-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 33% of the Option Shares shall vest on the one-year anniversary of the grant date. Thereafter, the remainder of the Option Shares shall vest in 8 equal amounts every 3 months beginning 3 months after the one-year anniversary date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 44,242 | $4.73 | $209,215.99 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · nonDerivative · entry 2 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,605 F1 · price: The price represents the weighted average price with a low of $4.70 and a high of $4.775. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:07 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionOrdinary Shares | 44,242 | $2.74 | $121,223.08 |
DisclosureSEC source: 0001562180-18-003770 · primarydocument.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2018 Filed Aug 17, 2018 16:05 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 88,831 | $4.66 | $413,739.27 |
DisclosureSEC source: 0001562180-18-003675 · primarydocument.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,605 F1 · price: The price represents the weighted average price with a low of $4.65 and a high of $4.70. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 16:22 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionStock Option (Rt to Buy) · Derivative | 88,831 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001209191-18-046227 · doc4.xml · derivative · entry 3 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 88,831 shares Expires 2018-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 16:22 UTC | SteadyMed Ltd. STDY · Entity 163743 | Exercise / conversionOrdinary Shares | 88,831 | $3.61 | $320,679.91 |
DisclosureSEC source: 0001209191-18-046227 · doc4.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 14:39 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 4,961 | $4.50 | $22,324.50 |
DisclosureSEC source: 0001104659-18-043808 · a4.xml · nonDerivative · entry 2 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,960 F1 · kind: Sales are pursuant to a 10b5-1 Plan. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 14:39 UTC | SteadyMed Ltd. STDY · Entity 163743 | SaleOrdinary Shares | 41,605 | $4.50 | $187,222.50 |
DisclosureSEC source: 0001104659-18-043808 · a4.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,605 F1 · kind: Sales are pursuant to a 10b5-1 Plan. Read SEC document |
| December 28, 2017 Filed Dec 28, 2017 15:31 UTC | SteadyMed Ltd. STDY · Entity 163743 | GrantStock Option (right to buy) · Derivative | 163,394 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-17-067564 · doc4.xml · derivative · entry 2 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,394 Underlying: Ordinary Shares · 163,394 shares Expires 2027-12-28 F3 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested. Read SEC document |
| December 28, 2017 Filed Dec 28, 2017 15:31 UTC | SteadyMed Ltd. STDY · Entity 163743 | GrantOrdinary Shares | 83,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067564 · doc4.xml · nonDerivative · entry 1 RIGBY JONATHAN · CIK 0001356227 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,210 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of SteadyMed Ltd. ordinary shares. F2 · shares: The restricted stock units ("RSUs")are 50% time-based and 50% performance based grants. 50% of the RSUs shall vest on June 30, 2018 and 50% shall vest upon approval by the FDA of the New Drug Application for Trevyent. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.